Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastroenteropancreatic Neuroendocrine Carcinoma”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Testing effectiveness (Phase 2)Study completedNCT03079440
What this trial is testing

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsNeuroendocrine CarcinomaTemozolomide+1 more
Asan Medical Center 31
Large-scale testing (Phase 3)Looking for participantsNCT06937905
What this trial is testing

Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 129
Testing effectiveness (Phase 2)Study completedNCT02575300
What this trial is testing

Phase II Study of Ibrutinib in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors

Who this might be right for
Carcinoid TumorsPancreatic NET
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Study completedNCT02248012
What this trial is testing

Everolimus and Temozolomide in Advanced Gastroenteropancreatic Neuroendocrine Carcinoma (G3)

Who this might be right for
Neuroendocrine Carcinoma
Haukeland University Hospital 38
Testing effectiveness (Phase 2)WithdrawnNCT05582031
What this trial is testing

Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Who this might be right for
Anal Squamous Cell CarcinomaColorectal NeoplasmsSoft Tissue Sarcoma+5 more
Translational Research in Oncology
Large-scale testing (Phase 3)Looking for participantsNCT05477576
What this trial is testing

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+4 more
RayzeBio, Inc. 338
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Early research (Phase 1)Study completedNCT01263353
What this trial is testing

Safety and Tolerability of Pasireotide LAR in Combination With Everolimus in Advanced Metastatic NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System
Novartis Pharmaceuticals 36
Testing effectiveness (Phase 2)Active Not RecruitingNCT02595424
What this trial is testing

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Who this might be right for
Gastric Neuroendocrine CarcinomaIntestinal Neuroendocrine CarcinomaPancreatic Neuroendocrine Carcinoma
ECOG-ACRIN Cancer Research Group 67
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Testing effectiveness (Phase 2)Study completedNCT03591731
What this trial is testing

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Who this might be right for
Neuroendocrine Carcinoma
Intergroupe Francophone de Cancerologie Thoracique 185
Testing effectiveness (Phase 2)UnknownNCT03475953
What this trial is testing

A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Who this might be right for
Colorectal Cancer Not MSI-H or MMR-deficientGISTOesophageal or Gastric Carcinoma+12 more
Institut Bergonié 747
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05385861
What this trial is testing

Nal-IRI (ONIVYDE® ) and Carboplatin in Patients With Advanced or Metastatic GEP-NET

Who this might be right for
GEP-NET
National Health Research Institutes, Taiwan 52
Testing effectiveness (Phase 2)Study completedNCT02611024
What this trial is testing

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Who this might be right for
Advanced Solid TumorsGlioblastomaSoft Tissue Sarcoma (Excluding GIST)+9 more
PharmaMar 316
Early research (Phase 1)Looking for participantsNCT07165132
What this trial is testing

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Who this might be right for
GEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor Disease+6 more
RayzeBio, Inc. 104
Post-approval studies (Phase 4)Study completedNCT04524442
What this trial is testing

Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Advanced Accelerator Applications 42
Testing effectiveness (Phase 2)Study completedNCT02955069
What this trial is testing

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

Who this might be right for
Well-differentiated Non-functional NET of Thoracic OriginWell-differentiated Non-functional NET of Gastrointestinal OriginWell-differentiated Non-functional NET of Pancreatic Origin+1 more
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT03042780
What this trial is testing

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Who this might be right for
Gastro-enteropancreatic Neuroendocrine TumorPancreatic CancerNeuroendocrine Carcinomas of Pancreas+1 more
H. Lee Moffitt Cancer Center and Research Institute 2
Testing effectiveness (Phase 2)Study completedNCT02250885
What this trial is testing

KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors

Who this might be right for
Carcinoma, Neuroendocrine
Gabrail Cancer Center Research 14
Testing effectiveness (Phase 2)Looking for participantsNCT07278479
What this trial is testing

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

Who this might be right for
Large Cell Neuroendocrine CarcinomaLarge Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC)Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)+4 more
Molecular Partners AG 138
Load More Results
116